FGF2 | Human | (+)-pilocarpine | multiple interactions | ISO | RGD:2609 | 6480464 | FGF2 inhibits the reaction [Pilocarpine results in increased expression of IL1B protein] | CTD | PMID:21087489 |
FGF2 | Human | (-)-epigallocatechin 3-gallate | decreases expression | EXP | | 6480464 | epigallocatechin gallate results in decreased expression of FGF2 mRNA | CTD | PMID:16084531 |
FGF2 | Human | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGF2 mRNA | CTD | PMID:22079256 |
FGF2 | Human | (R)-noradrenaline | multiple interactions | ISO | RGD:2609 | 6480464 | [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results more ... | CTD | PMID:11742803 |
FGF2 | Human | (S)-colchicine | affects expression | ISO | RGD:2609 | 6480464 | Colchicine affects the expression of FGF2 protein | CTD | PMID:7714246 |
FGF2 | Human | (S)-nicotine | decreases expression | ISO | RGD:2609 | 6480464 | Nicotine results in decreased expression of FGF2 protein | CTD | PMID:14732461 |
FGF2 | Human | (S)-nicotine | increases expression | ISO | RGD:70823 | 6480464 | Nicotine results in increased expression of FGF2 mRNA; Nicotine results in increased expression of FGF2 more ... | CTD | PMID:31622651|PMID:32512034 |
FGF2 | Human | (S)-nicotine | increases expression | ISO | RGD:2609 | 6480464 | Nicotine results in increased expression of FGF2 mRNA; Nicotine results in increased expression of FGF2 more ... | CTD | PMID:15465631|PMID:18190895|PMID:22198237|PMID:31622651|PMID:32512034|PMID:9503263|PMID:9832142 |
FGF2 | Human | (S)-nicotine | increases secretion | EXP | | 6480464 | Nicotine results in increased secretion of FGF2 protein | CTD | PMID:16365874|PMID:22198237 |
FGF2 | Human | (S)-nicotine | multiple interactions | EXP | | 6480464 | [triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]] which more ... | CTD | PMID:22198237 |
FGF2 | Human | (S)-nicotine | multiple interactions | ISO | RGD:2609 | 6480464 | Mecamylamine inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the more ... | CTD | PMID:22198237|PMID:9832142 |
FGF2 | Human | 1,2-dimethylhydrazine | multiple interactions | ISO | RGD:2609 | 6480464 | p-coumaric acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of FGF2 protein] | CTD | PMID:29879413 |
FGF2 | Human | 1,2-dimethylhydrazine | increases expression | ISO | RGD:2609 | 6480464 | 1,2-Dimethylhydrazine results in increased expression of FGF2 protein | CTD | PMID:29879413 |
FGF2 | Human | 1-(5-isoquinolinesulfonyl)-2-methylpiperazine | multiple interactions | ISO | RGD:2609 | 6480464 | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGF2 protein] | CTD | PMID:15654655 |
FGF2 | Human | 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | decreases expression | ISO | RGD:70823 | 6480464 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FGF2 mRNA | CTD | PMID:28801915 |
FGF2 | Human | 1-naphthyl isothiocyanate | multiple interactions | EXP | | 6480464 | [1-Naphthylisothiocyanate co-treated with Cholic Acids] affects the expression of FGF2 mRNA | CTD | PMID:27344345 |
FGF2 | Human | 14,15-EET | increases expression | EXP | | 6480464 | 14,15-epoxy-5,8,11-eicosatrienoic acid results in increased expression of FGF2 protein | CTD | PMID:16286479 |
FGF2 | Human | 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of FGF2 mRNA | CTD | PMID:21098263 |
FGF2 | Human | 17beta-estradiol | multiple interactions | EXP | | 6480464 | [Estradiol binds to ESR2 protein] which results in decreased expression of FGF2 mRNA; [Progesterone co-treated more ... | CTD | PMID:18692832|PMID:20404318 |
FGF2 | Human | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | EXP | | 6480464 | Dihydrotestosterone results in increased expression of FGF2 mRNA; Dihydrotestosterone results in increased expression of FGF2 more ... | CTD | PMID:20421132 |
FGF2 | Human | 17beta-hydroxy-5alpha-androstan-3-one | multiple interactions | EXP | | 6480464 | Flutamide inhibits the reaction [Dihydrotestosterone results in increased expression of FGF2 mRNA]; Flutamide inhibits the more ... | CTD | PMID:20421132 |
FGF2 | Human | 2,2',4,4'-Tetrabromodiphenyl ether | multiple interactions | ISO | RGD:70823 | 6480464 | 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [[EGF protein co-treated with FGF2 protein] results in increased more ... | CTD | PMID:23564643 |
FGF2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:70823 | 6480464 | Tetrachlorodibenzodioxin affects the expression of FGF2 mRNA | CTD | PMID:12167310 |
FGF2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of FGF2 mRNA | CTD | PMID:36370075 |
FGF2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of FGF2 mRNA | CTD | PMID:12377990|PMID:23625689|PMID:30096437 |
FGF2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | EXP | | 6480464 | 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FGF2 mRNA] | CTD | PMID:23625689 |
FGF2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases activity | ISO | RGD:70823 | 6480464 | Tetrachlorodibenzodioxin results in decreased activity of FGF2 protein | CTD | PMID:20486776|PMID:23212921 |
FGF2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:70823 | 6480464 | [Tetrachlorodibenzodioxin analog co-treated with FGF2 protein] results in increased expression of DSG1A mRNA; [Tetrachlorodibenzodioxin co-treated more ... | CTD | PMID:23212921 |
FGF2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:2609 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of FGF2 mRNA | CTD | PMID:21724226 |
FGF2 | Human | 2,3,7,8-Tetrachlorodibenzofuran | decreases expression | ISO | RGD:2609 | 6480464 | 2,3,7,8-tetrachlorodibenzofuran results in decreased expression of FGF2 mRNA | CTD | PMID:21724226 |
FGF2 | Human | 2-amino-2-deoxy-D-glucopyranose | multiple interactions | ISO | RGD:2609 | 6480464 | Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] | CTD | PMID:1518840 |
FGF2 | Human | 2-hydroxyethyl methacrylate | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [hydroxyethyl methacrylate results in increased secretion of FGF2 protein]; pyrazolanthrone inhibits more ... | CTD | PMID:19176594 |
FGF2 | Human | 2-hydroxyethyl methacrylate | increases secretion | EXP | | 6480464 | hydroxyethyl methacrylate results in increased secretion of FGF2 protein | CTD | PMID:19176594 |
FGF2 | Human | 3,3',4,4',5-pentachlorobiphenyl | decreases expression | ISO | RGD:2609 | 6480464 | 3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of FGF2 mRNA | CTD | PMID:23196670 |
FGF2 | Human | 3,3',4,4',5-pentachlorobiphenyl | increases expression | EXP | | 6480464 | 3,4,5,3',4'-pentachlorobiphenyl results in increased expression of FGF2 mRNA | CTD | PMID:35618242 |
FGF2 | Human | 3,3',5-triiodo-L-thyronine | multiple interactions | ISO | RGD:70823 | 6480464 | Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein]; Triiodothyronine promotes more ... | CTD | PMID:16150908 |
FGF2 | Human | 3,3',5-triiodo-L-thyronine | multiple interactions | ISO | RGD:2609 | 6480464 | [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results more ... | CTD | PMID:11742803|PMID:12805413 |
FGF2 | Human | 3,4-dihydroxybenzaldehyde | multiple interactions | EXP | | 6480464 | protocatechualdehyde inhibits the reaction [TGFB1 protein results in increased expression of FGF2 protein] | CTD | PMID:25582705 |
FGF2 | Human | 3,4-dihydroxybenzaldehyde | multiple interactions | ISO | RGD:2609 | 6480464 | protocatechualdehyde inhibits the reaction [Bleomycin results in increased expression of FGF2 protein] | CTD | PMID:25582705 |
FGF2 | Human | 3-\{1-[3-(dimethylamino)propyl]-1H-indol-3-yl\}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione | multiple interactions | ISO | RGD:2609 | 6480464 | bisindolylmaleimide I promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA] | CTD | PMID:11742803 |
FGF2 | Human | 3-\{1-[3-(dimethylamino)propyl]-1H-indol-3-yl\}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione | multiple interactions | ISO | RGD:70823 | 6480464 | bisindolylmaleimide I inhibits the reaction [FGF2 protein results in increased expression of RUNX2 mRNA] | CTD | PMID:12403780 |
FGF2 | Human | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:70823 | 6480464 | [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein; more ... | CTD | PMID:28285642 |
FGF2 | Human | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | EXP | | 6480464 | [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF more ... | CTD | PMID:29698629 |
FGF2 | Human | 3-Nitrobenzanthrone | increases expression | EXP | | 6480464 | 3-nitrobenzanthrone results in increased expression of FGF2 mRNA | CTD | PMID:34036453 |
FGF2 | Human | 3H-1,2-dithiole-3-thione | increases expression | ISO | RGD:2609 | 6480464 | 1,2-dithiol-3-thione results in increased expression of FGF2 mRNA | CTD | PMID:19162173 |
FGF2 | Human | 4,4'-sulfonyldiphenol | multiple interactions | EXP | | 6480464 | [bisphenol S co-treated with Fulvestrant] results in increased methylation of FGF2 gene | CTD | PMID:31601247 |
FGF2 | Human | 4-hydroxyphenyl retinamide | decreases expression | ISO | RGD:70823 | 6480464 | Fenretinide results in decreased expression of FGF2 mRNA | CTD | PMID:28973697 |
FGF2 | Human | 4-phenylbutyric acid | decreases expression | EXP | | 6480464 | 4-phenylbutyric acid results in decreased expression of FGF2 mRNA | CTD | PMID:14583596 |
FGF2 | Human | 5-(2-methylpiperazine-1-sulfonyl)isoquinoline | multiple interactions | ISO | RGD:2609 | 6480464 | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGF2 protein] | CTD | PMID:15654655 |
FGF2 | Human | 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of FGF2 mRNA | CTD | PMID:16510598 |
FGF2 | Human | 6-aminonicotinamide | multiple interactions | ISO | RGD:70823 | 6480464 | IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of FGF2 protein] | CTD | PMID:12898533 |
FGF2 | Human | 6-aminonicotinamide | increases expression | ISO | RGD:70823 | 6480464 | 6-Aminonicotinamide results in increased expression of FGF2 protein | CTD | PMID:12898533 |
FGF2 | Human | 6-propyl-2-thiouracil | decreases expression | ISO | RGD:2609 | 6480464 | Propylthiouracil results in decreased expression of FGF2 mRNA | CTD | PMID:24780913|PMID:33150595 |
FGF2 | Human | 6-propyl-2-thiouracil | increases methylation | ISO | RGD:2609 | 6480464 | Propylthiouracil results in increased methylation of FGF2 promoter | CTD | PMID:33150595 |
FGF2 | Human | acrolein | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of more ... | CTD | PMID:32699268 |
FGF2 | Human | acrylamide | multiple interactions | EXP | | 6480464 | Acrylamide analog inhibits the reaction [Trifluoroacetic Acid results in increased degradation of FGF2 protein]; Acrylamide more ... | CTD | PMID:14733594 |
FGF2 | Human | actinomycin D | multiple interactions | EXP | | 6480464 | Dactinomycin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA] | CTD | PMID:26800359 |
FGF2 | Human | actinomycin D | multiple interactions | ISO | RGD:2609 | 6480464 | Dactinomycin inhibits the reaction [FGF2 protein results in increased expression of SNCA protein] | CTD | PMID:12562524 |
FGF2 | Human | actinomycin D | decreases expression | EXP | | 6480464 | Dactinomycin results in decreased expression of FGF2 mRNA | CTD | PMID:26800359 |
FGF2 | Human | aflatoxin B1 | increases expression | EXP | | 6480464 | Aflatoxin B1 results in increased expression of FGF2 mRNA | CTD | PMID:27153756 |
FGF2 | Human | albuterol | multiple interactions | EXP | | 6480464 | [Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 more ... | CTD | PMID:18076728 |
FGF2 | Human | aldehydo-D-glucosamine | multiple interactions | ISO | RGD:2609 | 6480464 | Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] | CTD | PMID:1518840 |
FGF2 | Human | aldehydo-D-glucose | increases expression | ISO | RGD:2609 | 6480464 | Glucose results in increased expression of FGF2 mRNA; Glucose results in increased expression of FGF2 more ... | CTD | PMID:1518840|PMID:19759273 |
FGF2 | Human | aldehydo-D-glucose | decreases expression | EXP | | 6480464 | Glucose results in decreased expression of FGF2 mRNA | CTD | PMID:31655124 |
FGF2 | Human | aldehydo-D-glucose | multiple interactions | ISO | RGD:2609 | 6480464 | Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] | CTD | PMID:1518840 |
FGF2 | Human | all-trans-retinoic acid | multiple interactions | ISO | RGD:70823 | 6480464 | FGF2 protein promotes the reaction [Tretinoin results in increased expression of GAB2 protein]; FGF2 protein more ... | CTD | PMID:16009726 |
FGF2 | Human | all-trans-retinoic acid | decreases expression | ISO | RGD:2609 | 6480464 | Tretinoin results in decreased expression of FGF2 mRNA | CTD | PMID:20488242 |
FGF2 | Human | all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of FGF2 mRNA | CTD | PMID:21934132 |
FGF2 | Human | all-trans-retinoic acid | decreases response to substance | ISO | RGD:2609 | 6480464 | Tretinoin results in decreased susceptibility to FGF2 protein | CTD | PMID:11675954 |
FGF2 | Human | all-trans-retinoic acid | multiple interactions | ISO | RGD:2609 | 6480464 | Tretinoin inhibits the reaction [FGF2 protein results in increased expression of CCND3 mRNA]; Tretinoin inhibits more ... | CTD | PMID:11675954 |
FGF2 | Human | all-trans-retinoic acid | decreases response to substance | ISO | RGD:70823 | 6480464 | FGF2 protein results in decreased susceptibility to Tretinoin | CTD | PMID:16009726 |
FGF2 | Human | alliin | decreases secretion | EXP | | 6480464 | alliin results in decreased secretion of FGF2 protein | CTD | PMID:16351512 |
FGF2 | Human | alliin | multiple interactions | EXP | | 6480464 | alliin promotes the reaction [FGF2 protein results in increased expression of TP53 protein] | CTD | PMID:16351512 |
FGF2 | Human | alpha-D-galactose | multiple interactions | ISO | RGD:2609 | 6480464 | Alpinia oxyphylla fruit extract inhibits the reaction [Galactose results in increased expression of FGF2 protein] | CTD | PMID:30367734 |
FGF2 | Human | alpha-D-galactose | increases expression | ISO | RGD:2609 | 6480464 | Galactose results in increased expression of FGF2 protein | CTD | PMID:30367734 |
FGF2 | Human | alpha-naphthoflavone | multiple interactions | EXP | | 6480464 | alpha-naphthoflavone inhibits the reaction [Benzo(a)pyrene inhibits the reaction [FGF2 protein results in increased phosphorylation of more ... | CTD | PMID:20876236 |
FGF2 | Human | alpha-pinene | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of more ... | CTD | PMID:32699268 |
FGF2 | Human | ammonium chloride | affects expression | ISO | RGD:2609 | 6480464 | Ammonium Chloride affects the expression of FGF2 mRNA | CTD | PMID:16483693 |
FGF2 | Human | amphetamine | increases expression | ISO | RGD:2609 | 6480464 | Amphetamine results in increased expression of FGF2 protein | CTD | PMID:16338078 |
FGF2 | Human | amphetamine | affects expression | ISO | RGD:2609 | 6480464 | Amphetamine affects the expression of FGF2 protein | CTD | PMID:10854759 |
FGF2 | Human | anthra[1,9-cd]pyrazol-6(2H)-one | multiple interactions | EXP | | 6480464 | pyrazolanthrone inhibits the reaction [hydroxyethyl methacrylate results in increased secretion of FGF2 protein]; pyrazolanthrone inhibits more ... | CTD | PMID:12832416|PMID:19176594|PMID:26800359 |
FGF2 | Human | anthra[1,9-cd]pyrazol-6(2H)-one | multiple interactions | ISO | RGD:2609 | 6480464 | pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein] | CTD | PMID:28087833 |
FGF2 | Human | anthra[1,9-cd]pyrazol-6(2H)-one | multiple interactions | ISO | RGD:70823 | 6480464 | pyrazolanthrone inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein] | CTD | PMID:25290095 |
FGF2 | Human | antimycin A | increases expression | EXP | | 6480464 | Antimycin A results in increased expression of FGF2 mRNA | CTD | PMID:33512557 |
FGF2 | Human | apigenin | multiple interactions | EXP | | 6480464 | Apigenin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA] | CTD | PMID:26800359 |
FGF2 | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of FGF2 mRNA | CTD | PMID:33212167 |
FGF2 | Human | arsane | decreases expression | ISO | RGD:70823 | 6480464 | Arsenic results in decreased expression of FGF2 mRNA | CTD | PMID:24019935 |
FGF2 | Human | arsane | affects methylation | EXP | | 6480464 | Arsenic affects the methylation of FGF2 gene | CTD | PMID:25304211 |
FGF2 | Human | arsenic atom | decreases expression | ISO | RGD:70823 | 6480464 | Arsenic results in decreased expression of FGF2 mRNA | CTD | PMID:24019935 |
FGF2 | Human | arsenic atom | affects methylation | EXP | | 6480464 | Arsenic affects the methylation of FGF2 gene | CTD | PMID:25304211 |
FGF2 | Human | arsenite(3-) | increases expression | ISO | RGD:70823 | 6480464 | arsenite results in increased expression of FGF2 mRNA | CTD | PMID:15345372 |
FGF2 | Human | arsenous acid | multiple interactions | EXP | | 6480464 | Arsenic Trioxide inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Arsenic more ... | CTD | PMID:15723287 |
FGF2 | Human | arsenous acid | decreases expression | EXP | | 6480464 | Arsenic Trioxide results in decreased expression of FGF2 mRNA | CTD | PMID:22521957 |
FGF2 | Human | atrazine | increases expression | ISO | RGD:2609 | 6480464 | Atrazine results in increased expression of FGF2 mRNA | CTD | PMID:36841081 |
FGF2 | Human | Azoxymethane | multiple interactions | ISO | RGD:70823 | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 more ... | CTD | PMID:29950665 |
FGF2 | Human | bathocuproine disulfonic acid | multiple interactions | ISO | RGD:70823 | 6480464 | bathocuproine sulfonate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; bathocuproine more ... | CTD | PMID:22842628 |
FGF2 | Human | BAY 60-6583 | multiple interactions | ISO | RGD:70823 | 6480464 | 1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [BAY 60-6583 results in increased expression of FGF2 protein]; [BAY 60-6583 more ... | CTD | PMID:27590504 |
FGF2 | Human | BAY 60-6583 | increases expression | ISO | RGD:70823 | 6480464 | BAY 60-6583 results in increased expression of FGF2 protein | CTD | PMID:27590504 |
FGF2 | Human | beclomethasone | multiple interactions | EXP | | 6480464 | [Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 more ... | CTD | PMID:18076728 |
FGF2 | Human | beclomethasone | decreases activity | EXP | | 6480464 | Beclomethasone results in decreased activity of FGF2 protein | CTD | PMID:18076728 |
FGF2 | Human | benzalkonium chloride | affects response to substance | EXP | | 6480464 | FGF2 SNP affects the susceptibility to Benzalkonium Compounds | CTD | PMID:27206134 |
FGF2 | Human | benzene | increases expression | ISO | RGD:70823 | 6480464 | Benzene results in increased expression of FGF2 mRNA | CTD | PMID:37084897 |
FGF2 | Human | benzo[a]pyrene | multiple interactions | EXP | | 6480464 | alpha-naphthoflavone inhibits the reaction [Benzo(a)pyrene inhibits the reaction [FGF2 protein results in increased phosphorylation of more ... | CTD | PMID:20876236 |
FGF2 | Human | benzo[a]pyrene | affects methylation | EXP | | 6480464 | Benzo(a)pyrene affects the methylation of FGF2 intron; Benzo(a)pyrene affects the methylation of FGF2 promoter | CTD | PMID:27901495|PMID:30157460 |
FGF2 | Human | benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of FGF2 mRNA | CTD | PMID:19181443 |
FGF2 | Human | benzo[a]pyrene | decreases response to substance | EXP | | 6480464 | Benzo(a)pyrene results in decreased susceptibility to FGF2 protein | CTD | PMID:20876236 |
FGF2 | Human | beta-D-glucosamine | multiple interactions | ISO | RGD:2609 | 6480464 | Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] | CTD | PMID:1518840 |
FGF2 | Human | bis(2-ethylhexyl) phthalate | multiple interactions | ISO | RGD:70823 | 6480464 | [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated more ... | CTD | PMID:37021957 |
FGF2 | Human | bis(2-ethylhexyl) phthalate | increases expression | ISO | RGD:70823 | 6480464 | Diethylhexyl Phthalate results in increased expression of FGF2 mRNA | CTD | PMID:34319233 |
FGF2 | Human | bisphenol A | decreases expression | ISO | RGD:70823 | 6480464 | bisphenol A results in decreased expression of FGF2 mRNA | CTD | PMID:27022677 |
FGF2 | Human | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of FGF2 protein | CTD | PMID:37567409 |
FGF2 | Human | bisphenol A | decreases methylation | EXP | | 6480464 | bisphenol A results in decreased methylation of FGF2 gene | CTD | PMID:31601247 |
FGF2 | Human | bisphenol A | increases methylation | ISO | RGD:2609 | 6480464 | bisphenol A results in increased methylation of FGF2 gene | CTD | PMID:28505145 |
FGF2 | Human | bisphenol A | decreases expression | ISO | RGD:2609 | 6480464 | bisphenol A results in decreased expression of FGF2 mRNA | CTD | PMID:25181051|PMID:34947998 |
FGF2 | Human | bleomycin A2 | increases expression | ISO | RGD:2609 | 6480464 | Bleomycin results in increased expression of FGF2 protein | CTD | PMID:25582705 |
FGF2 | Human | bleomycin A2 | multiple interactions | ISO | RGD:70823 | 6480464 | Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of FGF2 protein] | CTD | PMID:30825431 |
FGF2 | Human | bleomycin A2 | increases expression | ISO | RGD:70823 | 6480464 | Bleomycin results in increased expression of FGF2 protein | CTD | PMID:30825431 |
FGF2 | Human | bleomycin A2 | multiple interactions | ISO | RGD:2609 | 6480464 | protocatechualdehyde inhibits the reaction [Bleomycin results in increased expression of FGF2 protein] | CTD | PMID:25582705 |
FGF2 | Human | boric acid | multiple interactions | ISO | RGD:70823 | 6480464 | boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in more ... | CTD | PMID:28285642 |
FGF2 | Human | bucladesine | multiple interactions | EXP | | 6480464 | [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF more ... | CTD | PMID:29698629 |
FGF2 | Human | Butylbenzyl phthalate | multiple interactions | ISO | RGD:70823 | 6480464 | [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated more ... | CTD | PMID:37021957 |
FGF2 | Human | C60 fullerene | decreases expression | ISO | RGD:2609 | 6480464 | fullerene C60 results in decreased expression of FGF2 mRNA | CTD | PMID:19167457 |
FGF2 | Human | cadmium atom | decreases expression | EXP | | 6480464 | Cadmium results in decreased expression of FGF2 mRNA | CTD | PMID:20570719 |
FGF2 | Human | cadmium atom | multiple interactions | EXP | | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of FGF2 more ... | CTD | PMID:35301059 |
FGF2 | Human | cadmium dichloride | multiple interactions | EXP | | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of FGF2 more ... | CTD | PMID:35301059 |
FGF2 | Human | Calcitonin gene-related peptide 1 | increases expression | ISO | RGD:2609 | 329849008 | calcitonin gene-related peptide increases expression of mRNA in rat brain after middle cerebral artery infarction | RGD | |
FGF2 | Human | Calphostin C | multiple interactions | ISO | RGD:70823 | 6480464 | calphostin C inhibits the reaction [FGF2 protein results in increased expression of and results in more ... | CTD | PMID:12403780 |
FGF2 | Human | cannabidiol | multiple interactions | ISO | RGD:70823 | 6480464 | Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of FGF2 protein] | CTD | PMID:30825431 |
FGF2 | Human | cannabidiol | increases expression | EXP | | 6480464 | Cannabidiol results in increased expression of FGF2 mRNA | CTD | PMID:27918106|PMID:36519830 |
FGF2 | Human | capsaicin | decreases expression | ISO | RGD:2609 | 6480464 | Capsaicin results in decreased expression of FGF2 protein | CTD | PMID:14521749 |
FGF2 | Human | carbon nanotube | increases expression | ISO | RGD:70823 | 6480464 | Nanotubes, Carbon results in increased expression of FGF2 mRNA | CTD | PMID:25554681 |
FGF2 | Human | carmustine | decreases response to substance | EXP | | 6480464 | FGF2 protein results in decreased susceptibility to Carmustine | CTD | PMID:20221717 |
FGF2 | Human | cerivastatin | decreases expression | ISO | RGD:2609 | 6480464 | cerivastatin results in decreased expression of FGF2 mRNA; cerivastatin results in decreased expression of FGF2 more ... | CTD | PMID:11479256 |
FGF2 | Human | chlorpromazine | multiple interactions | EXP | | 6480464 | [Chlorpromazine co-treated with Cholic Acids] affects the expression of FGF2 mRNA | CTD | PMID:27344345 |
FGF2 | Human | chlorpyrifos | decreases expression | ISO | RGD:2609 | 6480464 | Chlorpyrifos results in decreased expression of FGF2 mRNA | CTD | PMID:17589599 |
FGF2 | Human | chondroitin sulfate | affects binding | EXP | | 6480464 | [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein; Chondroitin Sulfates analog binds more ... | CTD | PMID:12221095|PMID:15385557 |
FGF2 | Human | cilazapril monohydrate | decreases expression | ISO | RGD:2609 | 6480464 | Cilazapril results in decreased expression of FGF2 mRNA; Cilazapril results in decreased expression of FGF2 more ... | CTD | PMID:9640960 |
FGF2 | Human | cilnidipine | decreases expression | ISO | RGD:2609 | 6480464 | cilnidipine results in decreased expression of FGF2 mRNA | CTD | PMID:16333380 |
FGF2 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of FGF2 mRNA; [Cisplatin results in decreased more ... | CTD | PMID:21858171|PMID:27392435|PMID:30871063 |
FGF2 | Human | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of FGF2 mRNA | CTD | PMID:27392435 |
FGF2 | Human | clozapine | increases expression | ISO | RGD:2609 | 6480464 | Clozapine results in increased expression of FGF2 mRNA | CTD | PMID:11264663 |
FGF2 | Human | cobalt dichloride | multiple interactions | ISO | RGD:70823 | 6480464 | [BAY 60-6583 co-treated with cobaltous chloride] results in increased expression of FGF2 protein | CTD | PMID:27590504 |
FGF2 | Human | cocaine | decreases expression | EXP | | 6480464 | Cocaine results in decreased expression of FGF2 mRNA | CTD | PMID:12629581 |
FGF2 | Human | colforsin daropate hydrochloride | increases expression | EXP | | 6480464 | Colforsin results in increased expression of FGF2 mRNA; Colforsin results in increased expression of FGF2 more ... | CTD | PMID:10320526 |
FGF2 | Human | copper atom | multiple interactions | EXP | | 6480464 | [Chelating Agents binds to Copper] which affects the expression of FGF2 mRNA | CTD | PMID:30911355 |
FGF2 | Human | copper(0) | multiple interactions | EXP | | 6480464 | [Chelating Agents binds to Copper] which affects the expression of FGF2 mRNA | CTD | PMID:30911355 |
FGF2 | Human | copper(II) chloride | increases expression | EXP | | 6480464 | cupric chloride results in increased expression of FGF2 mRNA | CTD | PMID:38568856 |
FGF2 | Human | copper(II) sulfate | multiple interactions | ISO | RGD:70823 | 6480464 | Copper Sulfate inhibits the reaction [SLC31A1 gene mutant form inhibits the reaction [FGF2 protein results more ... | CTD | PMID:22842628 |
FGF2 | Human | crocidolite asbestos | increases expression | EXP | | 6480464 | Asbestos, Crocidolite results in increased expression of FGF2 mRNA | CTD | PMID:18687144 |
FGF2 | Human | crocidolite asbestos | multiple interactions | EXP | | 6480464 | IL1RN protein promotes the reaction [Asbestos, Crocidolite results in increased secretion of FGF2 protein]; NLRP3 more ... | CTD | PMID:28056339 |
FGF2 | Human | crocidolite asbestos | multiple interactions | ISO | RGD:70823 | 6480464 | [CASP1 protein affects the susceptibility to Asbestos, Crocidolite] which affects the expression of FGF2 protein | CTD | PMID:28056339 |
FGF2 | Human | crocidolite asbestos | increases secretion | EXP | | 6480464 | Asbestos, Crocidolite results in increased secretion of FGF2 protein | CTD | PMID:28056339 |
FGF2 | Human | crocidolite asbestos | affects expression | EXP | | 6480464 | Asbestos, Crocidolite affects the expression of FGF2 mRNA | CTD | PMID:17331233 |
FGF2 | Human | Cuprizon | increases expression | ISO | RGD:2609 | 6480464 | Cuprizone results in increased expression of FGF2 mRNA | CTD | PMID:27523638 |
FGF2 | Human | Cuprizon | decreases expression | ISO | RGD:2609 | 6480464 | Cuprizone results in decreased expression of FGF2 mRNA | CTD | PMID:26577399 |
FGF2 | Human | curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of FGF2 protein | CTD | PMID:23555722 |
FGF2 | Human | curcumin | increases expression | EXP | | 6480464 | Curcumin results in increased expression of FGF2 protein | CTD | PMID:23555722 |
FGF2 | Human | cycloheximide | multiple interactions | ISO | RGD:2609 | 6480464 | Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Cycloheximide promotes the reaction more ... | CTD | PMID:15654655|PMID:9798919 |
FGF2 | Human | cyclosporin A | multiple interactions | EXP | | 6480464 | [Cyclosporine co-treated with Cholic Acids] affects the expression of FGF2 mRNA | CTD | PMID:27344345 |
FGF2 | Human | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of FGF2 mRNA | CTD | PMID:27989131|PMID:38447685 |
FGF2 | Human | D-glucose | increases expression | ISO | RGD:2609 | 6480464 | Glucose results in increased expression of FGF2 mRNA; Glucose results in increased expression of FGF2 more ... | CTD | PMID:1518840|PMID:19759273 |
FGF2 | Human | D-glucose | decreases expression | EXP | | 6480464 | Glucose results in decreased expression of FGF2 mRNA | CTD | PMID:31655124 |
FGF2 | Human | D-glucose | multiple interactions | ISO | RGD:2609 | 6480464 | Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] | CTD | PMID:1518840 |
FGF2 | Human | DDT | decreases expression | EXP | | 6480464 | DDT results in decreased expression of FGF2 mRNA | CTD | PMID:31521043 |
FGF2 | Human | deguelin | increases expression | EXP | | 6480464 | deguelin results in increased expression of FGF2 mRNA | CTD | PMID:33512557 |
FGF2 | Human | dermatan sulfate | affects binding | EXP | | 6480464 | [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein | CTD | PMID:15385557 |
FGF2 | Human | dermatan sulfate | increases activity | ISO | RGD:70823 | 6480464 | Dermatan Sulfate analog results in increased activity of FGF2 protein | CTD | PMID:15563459 |
FGF2 | Human | dexamethasone | multiple interactions | ISO | RGD:2609 | 6480464 | Dexamethasone inhibits the reaction [nitrofen results in decreased expression of FGF2 mRNA] | CTD | PMID:10646786 |
FGF2 | Human | dexamethasone | multiple interactions | ISO | RGD:70823 | 6480464 | [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein; more ... | CTD | PMID:27568862|PMID:28285642 |
FGF2 | Human | dextran sulfate | multiple interactions | ISO | RGD:70823 | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 more ... | CTD | PMID:29950665 |
FGF2 | Human | diallyl trisulfide | increases expression | EXP | | 6480464 | diallyl trisulfide results in increased expression of FGF2 mRNA | CTD | PMID:34995734 |
FGF2 | Human | diarsenic trioxide | decreases expression | EXP | | 6480464 | Arsenic Trioxide results in decreased expression of FGF2 mRNA | CTD | PMID:22521957 |
FGF2 | Human | diarsenic trioxide | multiple interactions | EXP | | 6480464 | Arsenic Trioxide inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Arsenic more ... | CTD | PMID:15723287 |
FGF2 | Human | diazepam | increases expression | EXP | | 6480464 | Diazepam results in increased expression of FGF2 mRNA | CTD | PMID:19114084 |
FGF2 | Human | diazinon | decreases expression | ISO | RGD:2609 | 6480464 | Diazinon results in decreased expression of FGF2 mRNA | CTD | PMID:17589599|PMID:19130878 |
FGF2 | Human | diazinon | decreases expression | ISO | RGD:70823 | 6480464 | Diazinon results in decreased expression of FGF2 mRNA | CTD | PMID:35934178 |
FGF2 | Human | diazinon | affects expression | ISO | RGD:2609 | 6480464 | Diazinon affects the expression of FGF2 mRNA | CTD | PMID:22546817 |
FGF2 | Human | dibutyl phthalate | multiple interactions | ISO | RGD:70823 | 6480464 | [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated more ... | CTD | PMID:37021957 |
FGF2 | Human | dichlorine | multiple interactions | ISO | RGD:2609 | 6480464 | [Ozone co-treated with Chlorine] affects the expression of FGF2 mRNA | CTD | PMID:18636392 |
FGF2 | Human | dichlorine | decreases expression | ISO | RGD:2609 | 6480464 | Chlorine results in decreased expression of FGF2 mRNA | CTD | PMID:18636392 |
FGF2 | Human | dieldrin | decreases expression | ISO | RGD:2609 | 6480464 | Dieldrin results in decreased expression of FGF2 mRNA | CTD | PMID:19130878 |
FGF2 | Human | dieldrin | affects expression | ISO | RGD:2609 | 6480464 | Dieldrin affects the expression of FGF2 mRNA | CTD | PMID:22546817 |
FGF2 | Human | diethyl phthalate | multiple interactions | ISO | RGD:70823 | 6480464 | [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated more ... | CTD | PMID:37021957 |
FGF2 | Human | diethylstilbestrol | decreases expression | ISO | RGD:2609 | 6480464 | Diethylstilbestrol results in decreased expression of FGF2 mRNA | CTD | PMID:17005392 |
FGF2 | Human | diisobutyl phthalate | multiple interactions | ISO | RGD:70823 | 6480464 | [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated more ... | CTD | PMID:37021957 |
FGF2 | Human | diisononyl phthalate | multiple interactions | ISO | RGD:70823 | 6480464 | [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated more ... | CTD | PMID:37021957 |
FGF2 | Human | dimethylarsinic acid | increases expression | ISO | RGD:70823 | 6480464 | Cacodylic Acid results in increased expression of FGF2 mRNA | CTD | PMID:15345372 |
FGF2 | Human | dioxygen | multiple interactions | ISO | RGD:2609 | 6480464 | Oxygen inhibits the reaction [Paraquat results in increased expression of FGF2 mRNA] | CTD | PMID:26722498 |
FGF2 | Human | dioxygen | multiple interactions | ISO | RGD:70823 | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of FGF2 mRNA | CTD | PMID:30529165 |
FGF2 | Human | diprotium oxide | increases expression | EXP | | 6480464 | Water results in increased expression of FGF2 mRNA | CTD | PMID:26800359 |
FGF2 | Human | divanadium pentaoxide | decreases expression | EXP | | 6480464 | vanadium pentoxide results in decreased expression of FGF2 mRNA | CTD | PMID:17459161 |
FGF2 | Human | dizocilpine maleate | increases expression | ISO | RGD:2609 | 6480464 | Dizocilpine Maleate results in increased expression of FGF2 mRNA | CTD | PMID:9832142 |
FGF2 | Human | dobutamine | affects response to substance | EXP | | 6480464 | FGF2 protein affects the susceptibility to Dobutamine | CTD | PMID:14583313 |
FGF2 | Human | dobutamine | affects response to substance | ISO | RGD:70823 | 6480464 | FGF2 protein affects the susceptibility to Dobutamine | CTD | PMID:10491406 |
FGF2 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression more ... | CTD | PMID:27188386 |
FGF2 | Human | doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of FGF2 mRNA | CTD | PMID:29803840 |
FGF2 | Human | entinostat | increases expression | EXP | | 6480464 | entinostat results in increased expression of FGF2 mRNA | CTD | PMID:26272509 |
FGF2 | Human | entinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression more ... | CTD | PMID:27188386 |
FGF2 | Human | Erionite | increases expression | ISO | RGD:70823 | 6480464 | erionite results in increased expression of FGF2 mRNA | CTD | PMID:29279043 |
FGF2 | Human | ethanol | increases expression | ISO | RGD:70823 | 405855870 | ethanol increases expression of FGF2 mRNA in dorsal striatum | RGD | |
FGF2 | Human | etoposide | affects response to substance | EXP | | 6480464 | FGF2 protein affects the susceptibility to Etoposide | CTD | PMID:16217747 |
FGF2 | Human | famotidine | multiple interactions | EXP | | 6480464 | [Famotidine co-treated with Sucralfate] results in increased expression of FGF2 mRNA | CTD | PMID:17717918 |
FGF2 | Human | fenoldopam | increases expression | ISO | RGD:2609 | 6480464 | Fenoldopam results in increased expression of FGF2 protein | CTD | PMID:12180796 |
FGF2 | Human | fenpyroximate | increases expression | EXP | | 6480464 | fenpyroximate results in increased expression of FGF2 mRNA | CTD | PMID:33512557 |
FGF2 | Human | finasteride | multiple interactions | ISO | RGD:2609 | 6480464 | Finasteride inhibits the reaction [Testosterone results in increased expression of FGF2 protein] | CTD | PMID:27866977 |
FGF2 | Human | fluoranthene | multiple interactions | ISO | RGD:70823 | 6480464 | [1-methylanthracene co-treated with fluoranthene] results in increased expression of FGF2 mRNA | CTD | PMID:28329830 |
FGF2 | Human | fluoxetine | multiple interactions | ISO | RGD:2609 | 6480464 | [Fluoxetine co-treated with olanzapine] results in increased expression of FGF2 mRNA | CTD | PMID:15158429 |
FGF2 | Human | flutamide | multiple interactions | EXP | | 6480464 | Flutamide inhibits the reaction [Dihydrotestosterone results in increased expression of FGF2 mRNA]; Flutamide inhibits the more ... | CTD | PMID:20421132 |
FGF2 | Human | flutamide | increases expression | ISO | RGD:2609 | 6480464 | Flutamide results in increased expression of FGF2 mRNA | CTD | PMID:24793618 |
FGF2 | Human | folic acid | increases expression | ISO | RGD:70823 | 6480464 | Folic Acid results in increased expression of FGF2 mRNA | CTD | PMID:25629700 |
FGF2 | Human | formoterol fumarate | multiple interactions | EXP | | 6480464 | [Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of more ... | CTD | PMID:18076728 |
FGF2 | Human | fulvestrant | multiple interactions | EXP | | 6480464 | [bisphenol S co-treated with Fulvestrant] results in increased methylation of FGF2 gene; Fulvestrant inhibits the more ... | CTD | PMID:20179196|PMID:31601247 |
FGF2 | Human | fulvestrant | multiple interactions | ISO | RGD:2609 | 6480464 | fulvestrant inhibits the reaction [naringin results in increased expression of FGF2 mRNA] | CTD | PMID:23596885 |
FGF2 | Human | furan | decreases methylation | ISO | RGD:2609 | 6480464 | furan results in decreased methylation of FGF2 gene | CTD | PMID:27387713 |
FGF2 | Human | furan | increases expression | ISO | RGD:2609 | 6480464 | furan results in increased expression of FGF2 mRNA | CTD | PMID:27387713 |
FGF2 | Human | furosemide | decreases expression | ISO | RGD:2609 | 6480464 | Furosemide results in decreased expression of FGF2 mRNA | CTD | PMID:16526316 |
FGF2 | Human | galactose | increases expression | ISO | RGD:2609 | 6480464 | Galactose results in increased expression of FGF2 protein | CTD | PMID:30367734 |
FGF2 | Human | galactose | multiple interactions | ISO | RGD:2609 | 6480464 | Alpinia oxyphylla fruit extract inhibits the reaction [Galactose results in increased expression of FGF2 protein] | CTD | PMID:30367734 |
FGF2 | Human | gamma-tocopherol | decreases expression | EXP | | 6480464 | Tocopherols results in decreased expression of FGF2 mRNA | CTD | PMID:15878867 |
FGF2 | Human | gemcitabine | multiple interactions | EXP | | 6480464 | [Gemcitabine co-treated with IFNA2 protein] results in increased expression of FGF2 protein | CTD | PMID:12738744 |
FGF2 | Human | gemcitabine | increases expression | EXP | | 6480464 | Gemcitabine results in increased expression of FGF2 protein | CTD | PMID:20531411 |
FGF2 | Human | genistein | multiple interactions | ISO | RGD:2609 | 6480464 | [Genistein co-treated with Methoxychlor] results in decreased expression of FGF2 mRNA | CTD | PMID:21782745 |
FGF2 | Human | genistein | increases expression | ISO | RGD:70823 | 6480464 | Genistein results in increased expression of FGF2 mRNA | CTD | PMID:32186404 |
FGF2 | Human | glucose | increases expression | ISO | RGD:2609 | 6480464 | Glucose results in increased expression of FGF2 mRNA; Glucose results in increased expression of FGF2 more ... | CTD | PMID:1518840|PMID:19759273 |
FGF2 | Human | glucose | decreases expression | EXP | | 6480464 | Glucose results in decreased expression of FGF2 mRNA | CTD | PMID:31655124 |
FGF2 | Human | glucose | multiple interactions | ISO | RGD:2609 | 6480464 | Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] | CTD | PMID:1518840 |
FGF2 | Human | glycidol | increases methylation | ISO | RGD:2609 | 6480464 | glycidol results in increased methylation of FGF2 promoter | CTD | PMID:33150595 |
FGF2 | Human | glycidol | decreases expression | ISO | RGD:2609 | 6480464 | glycidol results in decreased expression of FGF2 mRNA | CTD | PMID:33150645 |
FGF2 | Human | gossypol | decreases expression | EXP | | 6480464 | Gossypol results in decreased expression of FGF2 mRNA | CTD | PMID:19825521 |
FGF2 | Human | gossypol | multiple interactions | EXP | | 6480464 | zoledronic acid promotes the reaction [Gossypol results in decreased expression of FGF2 mRNA] | CTD | PMID:19825521 |
FGF2 | Human | haloperidol | multiple interactions | ISO | RGD:70823 | 405855870 | haloperidol inhibits the reaction [ethanol increases expression of FGF2 mRNA in dorsal striatum] | RGD | |
FGF2 | Human | heparan sulfate | multiple interactions | EXP | | 6480464 | Heparitin Sulfate binds to and affects the activity of FGF2 protein | CTD | PMID:15958608 |
FGF2 | Human | heparan sulfate | affects binding | ISO | RGD:70823 | 6480464 | Heparitin Sulfate binds to FGF2 protein | CTD | PMID:15464572 |
FGF2 | Human | heparan sulfate | increases activity | ISO | RGD:70823 | 6480464 | Heparitin Sulfate analog results in increased activity of FGF2 protein | CTD | PMID:12460940 |
FGF2 | Human | heparin | affects binding | EXP | | 6480464 | Heparin binds to FGF2 protein; Heparin binds to FGFR1 protein binds to FGF2 protein | CTD | PMID:15096041|PMID:17524524 |
FGF2 | Human | heparin | decreases expression | ISO | RGD:2609 | 6480464 | Heparin results in decreased expression of FGF2 protein | CTD | PMID:8441232 |
FGF2 | Human | heparin | affects binding | ISO | RGD:2609 | 6480464 | [Heparin binds to FGFR2 protein alternative form] which binds to FGF2 protein | CTD | PMID:10860838 |
FGF2 | Human | heparin | multiple interactions | ISO | RGD:2609 | 6480464 | Heparin affects the reaction [FGF2 protein binds to FGFR4 protein]; Heparin inhibits the reaction [FGF2 more ... | CTD | PMID:10336501|PMID:14966081 |
FGF2 | Human | heparin | affects activity | ISO | RGD:2609 | 6480464 | Heparin affects the activity of FGF2 protein | CTD | PMID:15232299 |
FGF2 | Human | heparin | multiple interactions | ISO | RGD:70823 | 6480464 | Heparin promotes the reaction [FGFR1 protein binds to FGF2 protein]; Heparin promotes the reaction [FGFR2 more ... | CTD | PMID:1373495|PMID:1379594 |
FGF2 | Human | hexadecanoic acid | multiple interactions | EXP | | 6480464 | [osteum co-treated with Palmitic Acid] results in increased expression of FGF2 mRNA; MRI-1867 inhibits the more ... | CTD | PMID:31454063 |
FGF2 | Human | Hexadimethrine bromide | decreases response to substance | EXP | | 6480464 | Hexadimethrine Bromide results in decreased susceptibility to FGF2 protein | CTD | PMID:21887340 |
FGF2 | Human | hydrogen chloride | decreases expression | EXP | | 6480464 | Hydrochloric Acid results in decreased expression of FGF2 mRNA | CTD | PMID:15046208 |
FGF2 | Human | hydrogen peroxide | multiple interactions | EXP | | 6480464 | Hydrogen Peroxide promotes the reaction [FGF2 protein binds to FGFR1 protein] | CTD | PMID:8849686 |
FGF2 | Human | hydrogen peroxide | multiple interactions | ISO | RGD:70823 | 6480464 | Hydrogen Peroxide inhibits the reaction [SLC31A1 gene mutant form inhibits the reaction [FGF2 protein results more ... | CTD | PMID:22842628 |
FGF2 | Human | iloprost | increases expression | EXP | | 6480464 | Iloprost results in increased expression of FGF2 mRNA | CTD | PMID:16373414 |
FGF2 | Human | iloprost | multiple interactions | EXP | | 6480464 | RTKI cpd inhibits the reaction [Iloprost results in increased expression of FGF2 mRNA] | CTD | PMID:16373414 |
FGF2 | Human | imiquimod | decreases expression | EXP | | 6480464 | imiquimod results in decreased expression of FGF2 | CTD | PMID:16368197 |
FGF2 | Human | indole-3-methanol | affects expression | ISO | RGD:2609 | 6480464 | indole-3-carbinol affects the expression of FGF2 mRNA | CTD | PMID:21396975 |
FGF2 | Human | indometacin | multiple interactions | ISO | RGD:2609 | 6480464 | Indomethacin inhibits the reaction [FGF2 protein results in increased expression of CCND1 protein]; Indomethacin inhibits more ... | CTD | PMID:11170841 |
FGF2 | Human | indometacin | increases expression | ISO | RGD:2609 | 6480464 | Indomethacin results in increased expression of FGF2 mRNA | CTD | PMID:17440234 |
FGF2 | Human | irinotecan | increases expression | EXP | | 6480464 | Irinotecan metabolite results in increased expression of FGF2 mRNA; Irinotecan results in increased expression of more ... | CTD | PMID:15956246 |
FGF2 | Human | Isradipine | increases secretion | EXP | | 6480464 | Isradipine results in increased secretion of FGF2 protein | CTD | PMID:15257873 |
FGF2 | Human | kaempferol | multiple interactions | ISO | RGD:2609 | 6480464 | [kaempferol inhibits the reaction [Lipopolysaccharides co-treated with TNF protein]] which results in increased expression of more ... | CTD | PMID:36049518 |
FGF2 | Human | kainic acid | increases expression | ISO | RGD:2609 | 6480464 | Kainic Acid results in increased expression of FGF2 mRNA | CTD | PMID:7649223 |
FGF2 | Human | lansoprazole | decreases expression | EXP | | 6480464 | Lansoprazole results in decreased expression of FGF2 protein | CTD | PMID:9881512 |
FGF2 | Human | Lasiocarpine | decreases expression | EXP | | 6480464 | lasiocarpine metabolite results in decreased expression of FGF2 mRNA | CTD | PMID:30465738 |
FGF2 | Human | lead diacetate | decreases expression | ISO | RGD:2609 | 6480464 | lead acetate results in decreased expression of FGF2 mRNA | CTD | PMID:22160880 |
FGF2 | Human | lead diacetate | increases expression | EXP | | 6480464 | lead acetate results in increased expression of FGF2 mRNA | CTD | PMID:38568856 |
FGF2 | Human | lead(0) | increases expression | EXP | | 6480464 | Lead results in increased expression of FGF2 | CTD | PMID:28395533 |
FGF2 | Human | leflunomide | increases expression | ISO | RGD:70823 | 6480464 | leflunomide results in increased expression of FGF2 mRNA | CTD | PMID:19751817 |
FGF2 | Human | leukotriene B4 | increases expression | ISO | RGD:70823 | 6480464 | Leukotriene B4 results in increased expression of FGF2 mRNA | CTD | PMID:30818366 |
FGF2 | Human | lipopolysaccharide | multiple interactions | ISO | RGD:70823 | 6480464 | coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of FGF2 protein]; Dexamethasone inhibits the more ... | CTD | PMID:27568862 |
FGF2 | Human | lipopolysaccharide | increases expression | ISO | RGD:2609 | 6480464 | Lipopolysaccharides results in increased expression of FGF2 protein | CTD | PMID:27098997|PMID:30980805 |
FGF2 | Human | lipopolysaccharide | multiple interactions | ISO | RGD:2609 | 6480464 | [kaempferol inhibits the reaction [Lipopolysaccharides co-treated with TNF protein]] which results in increased expression of more ... | CTD | PMID:27098997|PMID:30980805|PMID:36049518 |
FGF2 | Human | lipopolysaccharide | multiple interactions | EXP | | 6480464 | 2'-hydroxyflavanone inhibits the reaction [Lipopolysaccharides results in increased secretion of FGF2 protein]; valdecoxib affects the more ... | CTD | PMID:24431307|PMID:32800949 |
FGF2 | Human | lipopolysaccharide | increases secretion | EXP | | 6480464 | Lipopolysaccharides results in increased secretion of FGF2 protein | CTD | PMID:24431307|PMID:32800949 |
FGF2 | Human | lipopolysaccharide | increases expression | ISO | RGD:70823 | 6480464 | Lipopolysaccharides results in increased expression of FGF2 protein | CTD | PMID:27568862 |
FGF2 | Human | luteolin | multiple interactions | EXP | | 6480464 | Luteolin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA] | CTD | PMID:26800359 |
FGF2 | Human | LY294002 | multiple interactions | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased expression of and results in increased more ... | CTD | PMID:15631803|PMID:26800359 |
FGF2 | Human | LY294002 | decreases expression | ISO | RGD:70823 | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of FGF2 protein | CTD | PMID:29129800 |
FGF2 | Human | LY294002 | multiple interactions | ISO | RGD:2609 | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA] | CTD | PMID:11742803 |
FGF2 | Human | manganese(II) chloride | decreases expression | ISO | RGD:70823 | 6480464 | manganese chloride results in decreased expression of FGF2 mRNA | CTD | PMID:28801915 |
FGF2 | Human | manganese(II) chloride | increases methylation | ISO | RGD:2609 | 6480464 | manganese chloride results in increased methylation of FGF2 gene | CTD | PMID:28801915 |
FGF2 | Human | Mecamylamine | multiple interactions | ISO | RGD:2609 | 6480464 | Mecamylamine inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA] | CTD | PMID:9832142 |
FGF2 | Human | melittin | decreases expression | EXP | | 6480464 | Melitten results in decreased expression of FGF2 mRNA | CTD | PMID:18076793 |
FGF2 | Human | mercury atom | increases expression | EXP | | 6480464 | Mercury results in increased expression of FGF2 mRNA | CTD | PMID:16823088 |
FGF2 | Human | mercury(0) | increases expression | EXP | | 6480464 | Mercury results in increased expression of FGF2 mRNA | CTD | PMID:16823088 |
FGF2 | Human | methamphetamine | increases expression | ISO | RGD:2609 | 6480464 | Methamphetamine results in increased expression of FGF2 mRNA | CTD | PMID:19564919 |
FGF2 | Human | methoxychlor | multiple interactions | ISO | RGD:2609 | 6480464 | [Genistein co-treated with Methoxychlor] results in decreased expression of FGF2 mRNA | CTD | PMID:21782745 |
FGF2 | Human | methylarsonic acid | increases expression | ISO | RGD:70823 | 6480464 | monomethylarsonic acid results in increased expression of FGF2 mRNA | CTD | PMID:15345372 |
FGF2 | Human | methylmercury chloride | decreases expression | EXP | | 6480464 | methylmercuric chloride results in decreased expression of FGF2 mRNA | CTD | PMID:23179753|PMID:28001369 |
FGF2 | Human | methylmercury chloride | increases expression | ISO | RGD:2609 | 6480464 | methylmercuric chloride results in increased expression of FGF2 mRNA | CTD | PMID:31378766 |
FGF2 | Human | methylseleninic acid | decreases expression | EXP | | 6480464 | methylselenic acid results in decreased expression of FGF2 mRNA | CTD | PMID:12517777 |
FGF2 | Human | mitomycin C | increases expression | EXP | | 6480464 | Mitomycin results in increased expression of FGF2 protein | CTD | PMID:16585851 |
FGF2 | Human | MK-2206 | multiple interactions | ISO | RGD:2609 | 6480464 | [MK 2206 inhibits the reaction [Lipopolysaccharides co-treated with TNF protein]] which results in increased expression more ... | CTD | PMID:36049518 |
FGF2 | Human | monosodium L-glutamate | multiple interactions | ISO | RGD:70823 | 6480464 | [Sodium Glutamate co-treated with Trans Fatty Acids] results in increased expression of FGF2 mRNA | CTD | PMID:19001666 |
FGF2 | Human | morphine | decreases secretion | EXP | | 6480464 | Morphine results in decreased secretion of FGF2 protein | CTD | PMID:20564181 |
FGF2 | Human | morphine | multiple interactions | EXP | | 6480464 | Naloxone inhibits the reaction [Morphine results in decreased secretion of FGF2 protein]; OPRM1 protein affects more ... | CTD | PMID:20564181 |
FGF2 | Human | Morroniside | increases expression | ISO | RGD:2609 | 6480464 | morroniside results in increased expression of FGF2 protein | CTD | PMID:24979385 |
FGF2 | Human | N,N-diethyl-m-toluamide | multiple interactions | ISO | RGD:2609 | 6480464 | [Permethrin co-treated with DEET] results in decreased methylation of FGF2 gene; [Pyridostigmine Bromide co-treated with more ... | CTD | PMID:28659758|PMID:33148267 |
FGF2 | Human | N-acetyl-L-cysteine | decreases expression | EXP | | 6480464 | Acetylcysteine results in decreased expression of FGF2 mRNA | CTD | PMID:16084531 |
FGF2 | Human | N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [hydroxyethyl methacrylate results in increased secretion of FGF2 protein] | CTD | PMID:19176594 |
FGF2 | Human | N-methyl-4-phenylpyridinium | increases expression | EXP | | 6480464 | 1-Methyl-4-phenylpyridinium results in increased expression of FGF2 mRNA | CTD | PMID:25234470 |
FGF2 | Human | N-methyl-4-phenylpyridinium | increases methylation | ISO | RGD:2609 | 6480464 | 1-Methyl-4-phenylpyridinium results in increased methylation of FGF2 gene | CTD | PMID:28801915 |
FGF2 | Human | N-nitrosodiethylamine | increases expression | ISO | RGD:2609 | 6480464 | Diethylnitrosamine results in increased expression of FGF2 protein | CTD | PMID:24632418 |
FGF2 | Human | naloxone | multiple interactions | EXP | | 6480464 | Naloxone inhibits the reaction [Morphine results in decreased secretion of FGF2 protein] | CTD | PMID:20564181 |
FGF2 | Human | naringin | multiple interactions | ISO | RGD:2609 | 6480464 | fulvestrant inhibits the reaction [naringin results in increased expression of FGF2 mRNA] | CTD | PMID:23596885 |
FGF2 | Human | naringin | increases expression | ISO | RGD:2609 | 6480464 | naringin results in increased expression of FGF2 mRNA | CTD | PMID:23596885 |
FGF2 | Human | nickel atom | decreases expression | ISO | RGD:2609 | 6480464 | Nickel results in decreased expression of FGF2 mRNA | CTD | PMID:19130878 |
FGF2 | Human | nickel dichloride | affects expression | ISO | RGD:2609 | 6480464 | nickel chloride affects the expression of FGF2 mRNA | CTD | PMID:22546817 |
FGF2 | Human | nickel sulfate | increases expression | EXP | | 6480464 | nickel sulfate results in increased expression of FGF2 mRNA | CTD | PMID:22714537 |
FGF2 | Human | nicotine | increases expression | ISO | RGD:2609 | 6480464 | Nicotine results in increased expression of FGF2 mRNA; Nicotine results in increased expression of FGF2 more ... | CTD | PMID:15465631|PMID:18190895|PMID:22198237|PMID:31622651|PMID:32512034|PMID:9503263|PMID:9832142 |
FGF2 | Human | nicotine | increases expression | ISO | RGD:70823 | 6480464 | Nicotine results in increased expression of FGF2 mRNA; Nicotine results in increased expression of FGF2 more ... | CTD | PMID:31622651|PMID:32512034 |
FGF2 | Human | nicotine | increases secretion | EXP | | 6480464 | Nicotine results in increased secretion of FGF2 protein | CTD | PMID:16365874|PMID:22198237 |
FGF2 | Human | nicotine | multiple interactions | EXP | | 6480464 | [triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]] which more ... | CTD | PMID:22198237 |
FGF2 | Human | nicotine | multiple interactions | ISO | RGD:2609 | 6480464 | Mecamylamine inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the more ... | CTD | PMID:22198237|PMID:9832142 |
FGF2 | Human | nicotine | decreases expression | ISO | RGD:2609 | 6480464 | Nicotine results in decreased expression of FGF2 protein | CTD | PMID:14732461 |
FGF2 | Human | nifedipine | affects response to substance | EXP | | 6480464 | Nifedipine affects the susceptibility to FGF2 protein | CTD | PMID:15141722 |
FGF2 | Human | nifedipine | multiple interactions | EXP | | 6480464 | Nifedipine inhibits the reaction [FGF2 protein results in increased expression of FOS mRNA] | CTD | PMID:16188231 |
FGF2 | Human | nitrofen | multiple interactions | ISO | RGD:2609 | 6480464 | Dexamethasone inhibits the reaction [nitrofen results in decreased expression of FGF2 mRNA] | CTD | PMID:10646786 |
FGF2 | Human | nitrofen | decreases expression | ISO | RGD:2609 | 6480464 | nitrofen results in decreased expression of FGF2 mRNA | CTD | PMID:10646786|PMID:10898222 |
FGF2 | Human | nitroprusside | multiple interactions | ISO | RGD:2609 | 6480464 | FGF2 protein inhibits the reaction [Nitroprusside results in decreased expression of BCL2 protein]; FGF2 protein more ... | CTD | PMID:10203697 |
FGF2 | Human | nitroprusside | decreases response to substance | EXP | | 6480464 | FGF2 protein results in decreased susceptibility to Nitroprusside | CTD | PMID:10203697 |
FGF2 | Human | O-(chloroacetylcarbamoyl)fumagillol | multiple interactions | EXP | | 6480464 | [O-(chloroacetylcarbamoyl)fumagillol co-treated with docetaxel] results in decreased expression of FGF2 protein | CTD | PMID:12576464 |
FGF2 | Human | O-(chloroacetylcarbamoyl)fumagillol | decreases expression | EXP | | 6480464 | O-(chloroacetylcarbamoyl)fumagillol results in decreased expression of FGF2 protein | CTD | PMID:12576464 |
FGF2 | Human | olanzapine | multiple interactions | ISO | RGD:2609 | 6480464 | [Fluoxetine co-treated with olanzapine] results in increased expression of FGF2 mRNA | CTD | PMID:15158429 |
FGF2 | Human | Oxadiazon | multiple interactions | EXP | | 6480464 | ACYP2 protein affects the reaction [oxadiazon inhibits the reaction [FGF2 protein results in increased expression more ... | CTD | PMID:30391265 |
FGF2 | Human | oxilofrine | multiple interactions | EXP | | 6480464 | oxilofrine inhibits the reaction [VEGFA protein results in increased expression of FGF2 protein] | CTD | PMID:20643105 |
FGF2 | Human | oxybenzone | increases expression | EXP | | 6480464 | oxybenzone results in increased expression of FGF2 mRNA | CTD | PMID:36581016 |
FGF2 | Human | ozone | multiple interactions | ISO | RGD:2609 | 6480464 | [Ozone co-treated with Chlorine] affects the expression of FGF2 mRNA | CTD | PMID:18636392 |
FGF2 | Human | ozone | multiple interactions | ISO | RGD:70823 | 6480464 | [Air Pollutants results in increased abundance of Ozone] which results in increased expression of FGF2 more ... | CTD | PMID:27106289 |
FGF2 | Human | ozone | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in decreased expression of more ... | CTD | PMID:32699268 |
FGF2 | Human | paclitaxel | decreases response to substance | EXP | | 6480464 | FGF2 protein results in decreased susceptibility to Paclitaxel | CTD | PMID:16741658 |
FGF2 | Human | paracetamol | increases expression | ISO | RGD:70823 | 6480464 | Acetaminophen results in increased expression of FGF2 mRNA | CTD | PMID:21135413 |
FGF2 | Human | paracetamol | decreases expression | ISO | RGD:2609 | 6480464 | Acetaminophen results in decreased expression of FGF2 mRNA | CTD | PMID:33387578 |
FGF2 | Human | paracetamol | increases activity | ISO | RGD:2609 | 6480464 | Acetaminophen results in increased activity of FGF2 protein | CTD | PMID:25858767 |
FGF2 | Human | paracetamol | multiple interactions | ISO | RGD:70823 | 6480464 | FLT1 protein affects the reaction [Acetaminophen results in increased expression of FGF2 mRNA] | CTD | PMID:21135413 |
FGF2 | Human | paraquat | increases expression | ISO | RGD:2609 | 6480464 | Paraquat results in increased expression of FGF2 mRNA; Paraquat results in increased expression of FGF2 more ... | CTD | PMID:18198484|PMID:26722498|PMID:33015978 |
FGF2 | Human | paraquat | decreases secretion | EXP | | 6480464 | Paraquat results in decreased secretion of FGF2 protein | CTD | PMID:30698896 |
FGF2 | Human | paraquat | multiple interactions | ISO | RGD:2609 | 6480464 | HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of more ... | CTD | PMID:26722498|PMID:33015978 |
FGF2 | Human | parthenolide | multiple interactions | EXP | | 6480464 | parthenolide inhibits the reaction [FGF2 protein results in increased activity of [NFKB1 protein binds to more ... | CTD | PMID:16921510 |
FGF2 | Human | permethrin | multiple interactions | ISO | RGD:2609 | 6480464 | [Permethrin co-treated with DEET] results in decreased methylation of FGF2 gene; [Pyridostigmine Bromide co-treated with more ... | CTD | PMID:28659758|PMID:33148267 |
FGF2 | Human | phenylephrine | multiple interactions | ISO | RGD:2609 | 6480464 | Phenylephrine promotes the reaction [EGR1 protein binds to FGF2 promoter] | CTD | PMID:10779383 |
FGF2 | Human | phorbol 13-acetate 12-myristate | multiple interactions | ISO | RGD:2609 | 6480464 | Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Tetradecanoylphorbol Acetate promotes more ... | CTD | PMID:10779383|PMID:15654655 |
FGF2 | Human | phorbol 13-acetate 12-myristate | increases secretion | EXP | | 6480464 | Tetradecanoylphorbol Acetate results in increased secretion of FGF2 protein | CTD | PMID:11874475 |
FGF2 | Human | piroxicam | multiple interactions | EXP | | 6480464 | Cisplatin affects the reaction [Piroxicam results in decreased expression of FGF2 mRNA] | CTD | PMID:21858171 |
FGF2 | Human | piroxicam | decreases expression | EXP | | 6480464 | Piroxicam results in decreased expression of FGF2 mRNA | CTD | PMID:21858171 |
FGF2 | Human | platycodin D | decreases expression | ISO | RGD:2609 | 6480464 | platycodin D results in decreased expression of FGF2 protein | CTD | PMID:29595072 |
FGF2 | Human | potassium chromate | decreases expression | EXP | | 6480464 | potassium chromate(VI) results in decreased expression of FGF2 mRNA | CTD | PMID:22079256 |
FGF2 | Human | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGF2 mRNA | CTD | PMID:22079256 |
FGF2 | Human | potassium dichromate | decreases expression | EXP | | 6480464 | Potassium Dichromate results in decreased expression of FGF2 protein | CTD | PMID:23718831 |
FGF2 | Human | progesterone | multiple interactions | EXP | | 6480464 | [Progesterone co-treated with Estradiol] results in increased expression of FGF2 mRNA | CTD | PMID:18692832 |
FGF2 | Human | prostaglandin F2alpha | multiple interactions | ISO | RGD:2609 | 6480464 | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Cycloheximide inhibits the reaction more ... | CTD | PMID:15654655|PMID:16365892 |
FGF2 | Human | prostaglandin F2alpha | affects localization | ISO | RGD:2609 | 6480464 | Dinoprost affects the localization of FGF2 protein | CTD | PMID:15654655 |
FGF2 | Human | Pyridostigmine bromide | multiple interactions | ISO | RGD:2609 | 6480464 | [Pyridostigmine Bromide co-treated with DEET co-treated with Permethrin] results in increased expression of and results more ... | CTD | PMID:28659758 |
FGF2 | Human | quercetin | multiple interactions | EXP | | 6480464 | Quercetin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA] | CTD | PMID:26800359 |
FGF2 | Human | resveratrol | decreases activity | ISO | RGD:70823 | 6480464 | resveratrol results in decreased activity of FGF2 protein | CTD | PMID:16675471 |
FGF2 | Human | resveratrol | decreases expression | ISO | RGD:70823 | 6480464 | resveratrol results in decreased expression of FGF2 mRNA | CTD | PMID:25338179 |
FGF2 | Human | resveratrol | multiple interactions | ISO | RGD:70823 | 6480464 | resveratrol inhibits the reaction [FGF2 protein results in increased expression of TNFRSF11B mRNA]; resveratrol inhibits more ... | CTD | PMID:25290095 |
FGF2 | Human | resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of FGF2 mRNA; resveratrol results in decreased expression of FGF2 more ... | CTD | PMID:17935668|PMID:20028382 |
FGF2 | Human | rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of FGF2 mRNA | CTD | PMID:29955902|PMID:37394047 |
FGF2 | Human | rotenone | increases expression | ISO | RGD:70823 | 6480464 | Rotenone results in increased expression of FGF2 mRNA; Rotenone results in increased expression of FGF2 more ... | CTD | PMID:34045544 |
FGF2 | Human | rottlerin | multiple interactions | ISO | RGD:70823 | 6480464 | rottlerin inhibits the reaction [FGF2 protein results in increased activity of RUNX2 protein]; rottlerin inhibits more ... | CTD | PMID:12403780 |
FGF2 | Human | Rutecarpine | increases expression | EXP | | 6480464 | rutecarpine results in increased expression of FGF2 mRNA | CTD | PMID:34955744 |
FGF2 | Human | S-nitroso-N-acetyl-D-penicillamine | multiple interactions | EXP | | 6480464 | S-Nitroso-N-Acetylpenicillamine promotes the reaction [FGF2 protein results in increased expression of TP53 protein] | CTD | PMID:16351512 |
FGF2 | Human | SB 203580 | multiple interactions | EXP | | 6480464 | SB 203580 inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK14 protein]; SB more ... | CTD | PMID:15249425|PMID:15631803|PMID:26800359 |
FGF2 | Human | SB 203580 | increases secretion | ISO | RGD:2609 | 6480464 | SB 203580 results in increased secretion of FGF2 protein | CTD | PMID:28087833 |
FGF2 | Human | SB 203580 | multiple interactions | ISO | RGD:2609 | 6480464 | SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 more ... | CTD | PMID:21108934|PMID:28087833 |
FGF2 | Human | SB 203580 | multiple interactions | ISO | RGD:70823 | 6480464 | SB 203580 inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein] | CTD | PMID:25290095 |
FGF2 | Human | SB 203580 | decreases activity | EXP | | 6480464 | SB 203580 results in decreased activity of FGF2 protein | CTD | PMID:15249425 |
FGF2 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Sodium Chloride results in increased secretion of FGF2 protein]; [FGF2 protein more ... | CTD | PMID:26800359|PMID:27188386|PMID:32733202|PMID:34480604|PMID:37664457 |
FGF2 | Human | SCH772984 | increases secretion | ISO | RGD:2609 | 6480464 | SCH772984 results in increased secretion of FGF2 protein | CTD | PMID:28087833 |
FGF2 | Human | SCH772984 | multiple interactions | ISO | RGD:2609 | 6480464 | SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein] | CTD | PMID:28087833 |
FGF2 | Human | scutellarin | decreases expression | ISO | RGD:2609 | 6480464 | scutellarin results in decreased expression of FGF2 protein | CTD | PMID:16297343 |
FGF2 | Human | serpentine asbestos | increases secretion | EXP | | 6480464 | [Asbestos, Serpentine results in increased secretion of IL1B protein] which results in increased secretion of more ... | CTD | PMID:23017228 |
FGF2 | Human | serpentine asbestos | increases expression | ISO | RGD:2609 | 6480464 | Asbestos, Serpentine results in increased expression of FGF2 mRNA | CTD | PMID:9400719 |
FGF2 | Human | silibinin | multiple interactions | ISO | RGD:70823 | 6480464 | Silybin inhibits the reaction [Urethane results in increased secretion of FGF2 protein] | CTD | PMID:16788158 |
FGF2 | Human | silicon dioxide | increases secretion | EXP | | 6480464 | Silicon Dioxide results in increased secretion of FGF2 protein | CTD | PMID:22300531|PMID:25351596 |
FGF2 | Human | silicon dioxide | increases expression | EXP | | 6480464 | Silicon Dioxide results in increased expression of FGF2 mRNA | CTD | PMID:25351596 |
FGF2 | Human | silver atom | increases expression | EXP | | 6480464 | Silver results in increased expression of FGF2 mRNA | CTD | PMID:26551752 |
FGF2 | Human | silver(0) | increases expression | EXP | | 6480464 | Silver results in increased expression of FGF2 mRNA | CTD | PMID:26551752 |
FGF2 | Human | simvastatin | increases expression | EXP | | 6480464 | Simvastatin results in increased expression of FGF2 | CTD | PMID:20381859 |
FGF2 | Human | sodium arsenite | increases expression | EXP | | 6480464 | sodium arsenite results in increased expression of FGF2 mRNA | CTD | PMID:12703962|PMID:38568856 |
FGF2 | Human | sodium arsenite | increases expression | ISO | RGD:70823 | 6480464 | sodium arsenite results in increased expression of FGF2 mRNA | CTD | PMID:28370166 |
FGF2 | Human | sodium arsenite | decreases expression | EXP | | 6480464 | sodium arsenite results in decreased expression of FGF2 mRNA | CTD | PMID:19615344|PMID:34032870 |
FGF2 | Human | sodium chloride | increases expression | EXP | | 6480464 | Sodium Chloride results in increased expression of FGF2 mRNA | CTD | PMID:26800359 |
FGF2 | Human | sodium chloride | increases secretion | EXP | | 6480464 | Sodium Chloride results in increased secretion of FGF2 protein | CTD | PMID:26800359 |
FGF2 | Human | sodium chloride | multiple interactions | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]; 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits more ... | CTD | PMID:26800359 |
FGF2 | Human | Sodium oleate | multiple interactions | EXP | | 6480464 | [osteum co-treated with Palmitic Acid] results in increased expression of FGF2 mRNA; MRI-1867 inhibits the more ... | CTD | PMID:31454063 |
FGF2 | Human | Soman | increases expression | ISO | RGD:2609 | 6480464 | Soman results in increased expression of FGF2 mRNA | CTD | PMID:19281266 |
FGF2 | Human | Sucralfate | multiple interactions | EXP | | 6480464 | [Famotidine co-treated with Sucralfate] results in increased expression of FGF2 mRNA | CTD | PMID:17717918 |
FGF2 | Human | sucrose | increases expression | EXP | | 6480464 | Sucrose results in increased expression of FGF2 mRNA | CTD | PMID:26800359 |
FGF2 | Human | suramin | increases expression | EXP | | 6480464 | Suramin results in increased expression of FGF2 | CTD | PMID:8394679 |
FGF2 | Human | Swertiamarin | multiple interactions | ISO | RGD:2609 | 6480464 | swertiamarin inhibits the reaction [Testosterone results in increased expression of FGF2 protein] | CTD | PMID:27866977 |
FGF2 | Human | tamoxifen | decreases response to substance | EXP | | 6480464 | FGF2 protein results in decreased susceptibility to Tamoxifen | CTD | PMID:20179196 |
FGF2 | Human | tamoxifen | multiple interactions | EXP | | 6480464 | Tamoxifen inhibits the reaction [FGF2 protein results in increased expression of CCND1 protein] | CTD | PMID:20179196 |
FGF2 | Human | temozolomide | multiple interactions | ISO | RGD:2609 | 6480464 | [temozolomide co-treated with Thalidomide] results in decreased expression of FGF2 protein | CTD | PMID:16327979 |
FGF2 | Human | temozolomide | increases expression | EXP | | 6480464 | Temozolomide results in increased expression of FGF2 mRNA | CTD | PMID:31758290 |
FGF2 | Human | teniposide | decreases response to substance | EXP | | 6480464 | FGF2 protein results in decreased susceptibility to Teniposide | CTD | PMID:20221717 |
FGF2 | Human | testosterone | multiple interactions | ISO | RGD:2609 | 6480464 | Finasteride inhibits the reaction [Testosterone results in increased expression of FGF2 protein]; Qing Ye Dan more ... | CTD | PMID:27866977 |
FGF2 | Human | testosterone | increases expression | ISO | RGD:2609 | 6480464 | Testosterone results in increased expression of FGF2 protein | CTD | PMID:27866977 |
FGF2 | Human | tetrachloromethane | affects response to substance | ISO | RGD:70823 | 6480464 | FGF2 protein affects the susceptibility to Carbon Tetrachloride | CTD | PMID:14507672 |
FGF2 | Human | tetrachloromethane | increases expression | ISO | RGD:2609 | 6480464 | Carbon Tetrachloride results in increased expression of FGF2 mRNA; Carbon Tetrachloride results in increased expression more ... | CTD | PMID:16116963|PMID:17158861 |
FGF2 | Human | tetrathiomolybdate(2-) | multiple interactions | EXP | | 6480464 | [tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in more ... | CTD | PMID:18480265 |
FGF2 | Human | thalidomide | increases response to substance | EXP | | 6480464 | FGF2 protein results in increased susceptibility to Thalidomide | CTD | PMID:11555579 |
FGF2 | Human | thalidomide | decreases expression | EXP | | 6480464 | Thalidomide results in decreased expression of FGF2 protein | CTD | PMID:12644816|PMID:15863203 |
FGF2 | Human | thalidomide | multiple interactions | ISO | RGD:2609 | 6480464 | [Temozolomide co-treated with Thalidomide] results in decreased expression of FGF2 protein; HDAC6 protein inhibits the more ... | CTD | PMID:16327979|PMID:33015978 |
FGF2 | Human | thalidomide | decreases activity | EXP | | 6480464 | Thalidomide results in decreased activity of FGF2 protein | CTD | PMID:17557286 |
FGF2 | Human | thalidomide | multiple interactions | EXP | | 6480464 | Thalidomide promotes the reaction [FGF2 protein results in decreased expression of MMP2 protein] | CTD | PMID:14558594 |
FGF2 | Human | thalidomide | affects secretion | EXP | | 6480464 | Thalidomide affects the secretion of FGF2 protein | CTD | PMID:15939924 |
FGF2 | Human | thalidomide | affects expression | EXP | | 6480464 | Thalidomide affects the expression of FGF2 mRNA; Thalidomide affects the expression of FGF2 protein | CTD | PMID:15939924 |
FGF2 | Human | thyroxine | increases expression | ISO | RGD:70823 | 6480464 | Thyroxine results in increased expression of FGF2 mRNA | CTD | PMID:23935926 |
FGF2 | Human | titanium dioxide | multiple interactions | ISO | RGD:70823 | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 more ... | CTD | PMID:29950665 |
FGF2 | Human | titanium dioxide | increases expression | ISO | RGD:70823 | 6480464 | titanium dioxide results in increased expression of FGF2 mRNA | CTD | PMID:35295148 |
FGF2 | Human | tocopherol | decreases expression | EXP | | 6480464 | Tocopherols results in decreased expression of FGF2 mRNA | CTD | PMID:15878867 |
FGF2 | Human | topotecan | affects response to substance | EXP | | 6480464 | FGF2 protein affects the susceptibility to Topotecan | CTD | PMID:16217747 |
FGF2 | Human | trichloroethene | increases expression | ISO | RGD:2609 | 6480464 | Trichloroethylene results in increased expression of FGF2 mRNA | CTD | PMID:33387578 |
FGF2 | Human | trichostatin A | increases expression | ISO | RGD:70823 | 6480464 | trichostatin A results in increased expression of FGF2 mRNA | CTD | PMID:23463510 |
FGF2 | Human | trichostatin A | decreases expression | EXP | | 6480464 | trichostatin A results in decreased expression of FGF2 mRNA | CTD | PMID:24935251 |
FGF2 | Human | trifluoroacetic acid | multiple interactions | EXP | | 6480464 | Acrylamide analog inhibits the reaction [Trifluoroacetic Acid results in increased degradation of FGF2 protein] | CTD | PMID:14733594 |
FGF2 | Human | triphenylstannane | decreases expression | ISO | RGD:2609 | 6480464 | triphenyltin results in decreased expression of FGF2 mRNA | CTD | PMID:35489455 |
FGF2 | Human | triphenylstannane | decreases expression | ISO | RGD:70823 | 6480464 | triphenyltin results in decreased expression of FGF2 mRNA | CTD | PMID:35489455 |
FGF2 | Human | tyrphostin AG 1478 | multiple interactions | EXP | | 6480464 | RTKI cpd inhibits the reaction [Iloprost results in increased expression of FGF2 mRNA] | CTD | PMID:16373414 |
FGF2 | Human | urethane | multiple interactions | ISO | RGD:70823 | 6480464 | silybin inhibits the reaction [Urethane results in increased secretion of FGF2 protein] | CTD | PMID:16788158 |
FGF2 | Human | urethane | increases secretion | ISO | RGD:70823 | 6480464 | Urethane results in increased secretion of FGF2 protein | CTD | PMID:16788158 |
FGF2 | Human | valdecoxib | multiple interactions | EXP | | 6480464 | valdecoxib affects the reaction [Lipopolysaccharides results in increased secretion of FGF2 protein] | CTD | PMID:24431307 |
FGF2 | Human | valdecoxib | affects secretion | EXP | | 6480464 | valdecoxib affects the secretion of FGF2 protein | CTD | PMID:24431307 |
FGF2 | Human | valproic acid | increases expression | ISO | RGD:2609 | 6480464 | Valproic Acid results in increased expression of FGF2 mRNA; Valproic Acid results in increased expression more ... | CTD | PMID:28693025 |
FGF2 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of FGF2 mRNA | CTD | PMID:23179753|PMID:24935251|PMID:28001369 |
FGF2 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of FGF2 mRNA | CTD | PMID:25979313 |
FGF2 | Human | water | increases expression | EXP | | 6480464 | Water results in increased expression of FGF2 mRNA | CTD | PMID:26800359 |
FGF2 | Human | zinc atom | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of FGF2 mRNA | CTD | PMID:18593933 |
FGF2 | Human | zinc(0) | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of FGF2 mRNA | CTD | PMID:18593933 |
FGF2 | Human | zoledronic acid | decreases expression | EXP | | 6480464 | zoledronic acid results in decreased expression of FGF2 mRNA | CTD | PMID:24714768 |
FGF2 | Human | zoledronic acid | multiple interactions | EXP | | 6480464 | zoledronic acid promotes the reaction [Gossypol results in decreased expression of FGF2 mRNA] | CTD | PMID:19825521 |